Literature DB >> 19592120

Gender and age-dependent differences in the bradykinin-degradation within the pericardial fluid of patients with coronary artery disease.

Roland Bechtloff1, Andreas Goette, Alicja Bukowska, Thilo Kähne, Brigitte Peters, Christof Huth, Carmen Wolke, Uwe Lendeckel.   

Abstract

Cardiovascular diseases (CVD) and, in particular, coronary artery disease (CAD) are the leading causes of death in developed countries, especially in the elderly population. Males exhibit a higher risk for cardiovascular events than women. The pericardial fluid (PF) is in direct contact with the epicardial sections of the coronary arteries and the perimyocardium. A systematic analysis of gender-specific or age-related differences in angiotensin-related pathways like bradykinin metabolism however, has not been performed in the PF so far. Therefore, the amounts of angiotensin-converting enzyme (ACE) and the rate of the degradation of bradykinin (BK) and the amounts/activity of major BK-degrading enzymes, aminopeptidase N (APN) and dipeptidyl-aminopeptidase IV (DPIV), were assessed in the pericardial fluid (PF) of 44 patients undergoing coronary artery bypass grafting. We found BK being degraded within the PF. Interestingly, there was an age-dependent decrease in the amounts of ACE protein in women. In elderly women, ACE/APN and ACE/DPIV ratios were substantially reduced to 41.4% or 29.4% respectively (p<0.05). In contrast, an age-dependent decline of ACE protein and ACE/protease ratios were not found in men. In men and women, total BK degradation correlated with age (r=0.5; p=0.021) further supporting a switch in BK metabolising enzymes in elderly women. Thus, we can show age- and gender-dependent differences in BK metabolism within the PF in patients with coronary artery disease. The present finding that the expression of ACE is lowest in elderly women, despite the presence of similar BK degradation, might help to explain the potentially reduced therapeutic effects of ACE inhibitors in elderly women.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592120     DOI: 10.1016/j.ijcard.2009.06.028

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men.

Authors:  A Bukowska; L Spiller; C Wolke; U Lendeckel; S Weinert; J Hoffmann; P Bornfleth; I Kutschka; A Gardemann; B Isermann; A Goette
Journal:  Exp Biol Med (Maywood)       Date:  2017-06-29

2.  Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Authors:  Carmen Wolke; Alexander Teumer; Karlhans Endlich; Nicole Endlich; Rainer Rettig; Sylvia Stracke; Beate Fiene; Simone Aymanns; Stephan B Felix; Anke Hannemann; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-30

3.  Pericardial Parietal Mesothelial Cells: Source of the Angiotensin-Converting-Enzyme of the Bovine Pericardial Fluid.

Authors:  Ilsione Ribeiro de Sousa; Isabela Cabral Cavicchioli Pereira; Lourimar José de Morais; Livia das Graças Vieito Lombardi Teodoro; Maria Laura Pinto Rodrigues; Roseli Aparecida da Silva Gomes
Journal:  Arq Bras Cardiol       Date:  2017-11       Impact factor: 2.000

4.  Aberrant Epicardial Adipose Tissue Extracellular Matrix Remodeling in Patients with Severe Ischemic Cardiomyopathy: Insight from Comparative Quantitative Proteomics.

Authors:  Ding-Sheng Jiang; Hao-Long Zeng; Rui Li; Bo Huo; Yun-Shu Su; Jing Fang; Qing Yang; Li-Gang Liu; Min Hu; Cai Cheng; Xue-Hai Zhu; Xin Yi; Xiang Wei
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

5.  The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats.

Authors:  P L M Dalpiaz; A Z Lamas; I F Caliman; A R S Medeiros; G R Abreu; M R Moysés; T U Andrade; M F Alves; A K Carmona; N S Bissoli
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.